Delayed
London S.E.
03:33:02 29/04/2024 pm IST
|
5-day change
|
1st Jan Change
|
49.75
GBX
|
+1.95%
|
|
+10.31%
|
-57.77%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
31.94
|
29.79
|
284.3
|
316.8
|
298.4
|
173.4
|
173.4
|
-
|
Enterprise Value (EV)
1 |
26.72
|
21
|
238.5
|
290.6
|
275.3
|
157.2
|
166.1
|
171.3
|
P/E ratio
|
-2.26
x
|
-1.33
x
|
-
|
-
|
-7.49
x
|
-5.88
x
|
-4.32
x
|
-4.07
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
11.6
x
|
5.41
x
|
78.2
x
|
108
x
|
30.9
x
|
7.51
x
|
6.64
x
|
5.94
x
|
EV / Revenue
|
9.67
x
|
3.81
x
|
65.6
x
|
98.8
x
|
28.5
x
|
6.81
x
|
6.36
x
|
5.86
x
|
EV / EBITDA
|
-3.53
x
|
-1.53
x
|
-16.7
x
|
-10.9
x
|
-11.6
x
|
-9.96
x
|
-7.55
x
|
-11.1
x
|
EV / FCF
|
-3.34
x
|
-1.54
x
|
-19.7
x
|
-13.3
x
|
17.4
x
|
-8.74
x
|
-6.15
x
|
-6.81
x
|
FCF Yield
|
-29.9%
|
-65.1%
|
-5.07%
|
-7.51%
|
5.75%
|
-11.4%
|
-16.3%
|
-14.7%
|
Price to Book
|
0.98
x
|
0.8
x
|
-
|
-
|
-
|
-7.08
x
|
-9.34
x
|
-3.64
x
|
Nbr of stocks (in thousands)
|
1,04,710
|
1,72,703
|
2,49,420
|
2,50,617
|
2,59,438
|
3,55,250
|
3,55,250
|
-
|
Reference price
2 |
0.3050
|
0.1725
|
1.140
|
1.264
|
1.150
|
0.4880
|
0.4880
|
0.4880
|
Announcement Date
|
02/10/18
|
06/05/20
|
22/04/21
|
06/04/22
|
25/04/23
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
2.763
|
5.511
|
3.636
|
2.941
|
9.653
|
23.08
|
26.12
|
29.21
|
EBITDA
1 |
-7.575
|
-13.74
|
-14.29
|
-26.71
|
-23.67
|
-15.78
|
-22.01
|
-15.48
|
EBIT
1 |
-10.43
|
-17.69
|
-16.44
|
-29.08
|
-26.68
|
-24.22
|
-28.88
|
-25.76
|
Operating Margin
|
-377.52%
|
-321.01%
|
-452.26%
|
-988.88%
|
-276.44%
|
-104.91%
|
-110.57%
|
-88.19%
|
Earnings before Tax (EBT)
1 |
-10.39
|
-18.05
|
-21.34
|
-
|
-41.64
|
-33.35
|
-40
|
-41.3
|
Net income
1 |
-8.829
|
-15.62
|
-18.89
|
-
|
-39.19
|
-23.2
|
-32.2
|
-33
|
Net margin
|
-319.54%
|
-283.34%
|
-519.55%
|
-
|
-405.98%
|
-100.5%
|
-123.27%
|
-112.99%
|
EPS
2 |
-0.1349
|
-0.1298
|
-
|
-
|
-0.1535
|
-0.0830
|
-0.1130
|
-0.1200
|
Free Cash Flow
1 |
-7.991
|
-13.67
|
-12.09
|
-21.82
|
15.84
|
-17.98
|
-26.99
|
-25.15
|
FCF margin
|
-289.21%
|
-248.03%
|
-332.4%
|
-741.92%
|
164.07%
|
-77.88%
|
-103.33%
|
-86.11%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/10/18
|
06/05/20
|
22/04/21
|
06/04/22
|
25/04/23
|
-
|
-
|
-
|
Fiscal Period: December |
2022 S1
|
2022 S2
|
---|
Net sales
1 |
-
|
4.136
|
EBITDA
|
-
|
-
|
EBIT
|
-
|
-
|
Operating Margin
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-31.99
|
Net income
|
-7.935
|
-
|
Net margin
|
-
|
-
|
EPS
|
-0.0316
|
-
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
29/09/22
|
25/04/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
5.22
|
8.79
|
45.9
|
26.2
|
23.1
|
16.2
|
7.3
|
2.1
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-7.99
|
-13.7
|
-12.1
|
-21.8
|
15.8
|
-18
|
-27
|
-25.1
|
ROE (net income / shareholders' equity)
|
-34.4%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
0.3100
|
0.2100
|
-
|
-
|
-
|
-0.0700
|
-0.0500
|
-0.1300
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.58
|
0.62
|
1.44
|
1.31
|
0.59
|
2
|
1.85
|
1
|
Capex / Sales
|
20.92%
|
11.21%
|
39.71%
|
44.68%
|
6.15%
|
8.66%
|
7.08%
|
3.42%
|
Announcement Date
|
02/10/18
|
06/05/20
|
22/04/21
|
06/04/22
|
25/04/23
|
-
|
-
|
-
|
Last Close Price
0.488
GBP Average target price
0.9233
GBP Spread / Average Target +89.21% Consensus |
1st Jan change
|
Capi.
|
---|
| -57.77% | 216M | | -2.31% | 103B | | +0.56% | 95.28B | | +0.67% | 22.15B | | -17.37% | 21.02B | | -8.26% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|